Meta-organismal色氨酸代谢:CKD-MBD有吸引力的治疗靶点
慢性肾脏病-矿物质与骨异常(CKD-MBD)治疗面临挑战,2023年马德里KDIGO争议会议倡导整体性方法替代以甲状旁腺激素-钙磷为中心的策略。本文综述FGF23-α-Klotho轴及Meta-organismal色氨酸代谢紊乱作为CKD相关骨质疏松和心血管疾病的新型致病驱动因素,色氨酸代谢物如硫酸吲哚酚、犬尿氨酸和犬尿喹啉酸可能通过直接细胞毒性或激活芳香烃受体发挥心血管和骨骼毒性,同时创造新的治疗机会。
要点
- CKD-MBD传统干预未达预期,KDIGO倡导整体性方法。
- FGF23-α-Klotho轴是矿物质代谢关键调节因子和潜在治疗靶点。
- 色氨酸代谢物如硫酸吲哚酚、犬尿氨酸等可能具心血管和骨骼毒性。
核心结论
- Meta-organismal色氨酸代谢紊乱是CKD-MBD的新型致病驱动因素和潜在治疗靶点。
研究设计与样本
- 本文为综述,检索范围未报告。
主要发现
- CKD扰乱微生物和 endogenous 色氨酸代谢并导致色氨酸代谢物积累,部分为尿毒症毒素。
- 硫酸吲哚酚、犬尿氨酸和犬尿喹啉酸可能通过直接细胞毒性或激活芳香烃受体 confer 心血管和骨骼毒性。
临床怎么用
- 色氨酸代谢通路可能为CKD-MBD提供新的治疗机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite important advances over the past few decades, chronic kidney disease-mineral and bone disorder remains a major clinical therapeutic challenge. Traditional interventions targeting hyperphosphatemia, impaired vitamin D metabolism, and secondary hyperparathyroidism overall failed to meet expectations. This calls for a paradigm shift. The 2023 Madrid Chronic Kidney Disease-Mineral and Bone Disorder Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference advocated a holistic approach to replace the current parathyroid hormone-calcium phosphate-centric approach. In this context, the fibroblast growth factor 23-α-Klotho axis has emerged as a key regulator of mineral metabolism and a potential novel therapeutic target. In parallel, meta-organismal tryptophan dysmetabolism recently gained interest as a novel pathogenic driver of both chronic kidney disease-associated osteoporosis and cardiovascular disease. Chronic kidney disease not only profoundly disturbs microbial and endogenous tryptophan metabolism, but also causes accumulation of tryptophan metabolites, some of which are increasingly recognized as uremic toxins, including indoxyl sulfate, kynurenine, and kynurenic acid. They may confer cardiovascular and skeletal toxicity either by inducing direct cellular toxicity or by activating the aryl hydrocarbon receptor. While adding another level of complexity to the pathogenesis of chronic kidney disease-mineral and bone disorder, these insights also create novel therapeutic opportunities.
引用
- Fernandes G, Burtey S, Zadora W, et al. Meta-organismal tryptophan metabolism: an appealing therapeutic target in CKD-MBD. Kidney Int. 2025. PMID: 41448460. doi:10.1016/j.kint.2025.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。